Clinical, neuroradiological and genetic findings in pontocerebellar hypoplasia

Yasmin Namavar,1 Peter G. Barth,2 Paul R. Kasher,1 Knut Brockmann,3 Günter Bernert,4 Karin Writzl,5 Karen Ventura,6 Edith Y. Cheng,7 Donna M. Ferriero,8 Lina Basel-Vanagaite,9 Veerle R. C. Eggens,1 Ingeborg Krägeloh-Mann,10 Linda De Meirleir,11 Mary King,12 John M. Graham Jr,13 Arpad von Moers,14 Nine Knoers,15 Laszlo Sztriha,16 Rudolf Korintthenberg,17 PCH Consortium, * William B. Dobyns,18 Frank Baas1,19 and Bwee Tien Poll-The2

1 Department of Genome Analysis, Academic Medical Centre, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
2 Division of Paediatric Neurology, Emma’s Childrens Hospital, Academic Medical Centre, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
3 Paediatrics and Child Neurology, Georg August University, 37075 Goettingen, Germany
4 Kaiser Franz Josef Spital, Sozialmedizinische Zentrum Sud, 1100 Vienna, Austria
5 Institute Of Medical Genetics, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia
6 University of Virginia, Department of Obstetrics and Gynaecology, Charlottesville, VA 22908, USA
7 Divisions of Maternal Foetal Medicine and Medical Genetics, Departments of Obstetrics and Gynaecology and Internal Medicine, University of Washington, Seattle, WA 98201, USA
8 Department of Neurology, University of California San Francisco, San Francisco, CA 94143, USA
9 Schneider Children’s Medical Centre of Israel and Raphael Recanati Genetics Institute, Rabin Medical Centre, Petah Tikva, Israel and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
10 Department of Paediatric Neurology and Developmental Medicine, University of Tübingen, D-72076 Tübingen, Germany
11 University Hospital, Vrije Universiteit Brussels, 1050 Eisene, Belgium
12 Neurology Department, Children’s University Hospital, Temple Street, Dublin 1, Ireland
13 Medical Genetics Institute, Cedars-Sinai Medical Centre, David Geffen School of Medicine at UCLA, Los Angeles, CA 90048, USA
14 Deutsches Rotes Kreuz Kliniken Berlin Westend, Akademisches Lehrkrankenhaus der Charité-Universitätsmedizin, 14050 Berlin, Germany
15 Department of Human Genetics, Radboud University Nijmegen Medical Centre, 6525 GA Nijmegen, The Netherlands
16 Department of Paediatrics, Division B, University of Szeged, Szeged, H-6726, Hungary
17 University Medical Centre Freiburg, Department of Paediatrics and Adolescent Medicine, Division of Neuropaediatrics and Muscular Disorders, D-79106 Freiburg, Germany
18 Department of Human Genetics, University of Chicago, Chicago, IL 60637, USA
19 Department of Neurology, Academic Medical Centre, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands

*PCH Consortium is listed in Appendix 1.

Correspondence to: Frank Baas,
Department of Genome Analysis,
Academic Medical Centre,
Meibergdreef 9,
1105AZ Amsterdam,
The Netherlands
E-mail: f.baas@amc.uva.nl

Pontocerebellar hypoplasia is a group of autosomal recessive neurodegenerative disorders with prenatal onset. The common characteristics are cerebellar hypoplasia with variable atrophy of the cerebellum and the ventral pons. Supratentorial involvement is reflected by variable neocortical atrophy, ventriculomegaly and microcephaly. Mutations in the transfer RNA splicing...
endonuclease subunit genes (TSEN54, TSEN2, TSEN34) were found to be associated with pontocerebellar hypoplasia types 2 and 4. Mutations in the mitochondrial transfer RNA arginyl synthetase gene (RARS2) were associated with pontocerebellar hypoplasia type 6. We studied a cohort of 169 patients from 141 families for mutations in these genes, of whom 106 patients tested positive for mutations in one of the TSEN genes or the RARS2 gene. In order to delineate the neuroradiological and clinical phenotype of patients with mutations in these genes, we compared this group with 63 patients suspected of pontocerebellar hypoplasia who were negative on mutation analysis. We found a strong correlation (P < 0.0005) between TSEN54 mutations and a dragonfly-like cerebellar pattern on magnetic resonance imaging, in which the cerebellar hemispheres are flat and severely reduced in size and the vermis is relatively spared. Mutations in TSEN54 are clinically associated with dystonia and/or dystonia and variable degrees of spasticity, in some cases with pure generalized spasticity. Nonsense or splice site mutations in TSEN54 are associated with a more severe phenotype of more perinatal symptoms, ventilator dependency and early death. In addition, we present ten new mutations in TSEN54, TSEN2 and RARS2. Furthermore, we show that pontocerebellar hypoplasia type 1 together with elevated cerebrospinal fluid lactate may be caused by RARS2 mutations.

**Keywords:** pontocerebellar hypoplasia; TSEN; RARS2; neuroimaging; neurogenetics

**Abbreviations:** RARS2 = mitochondrial transfer RNA arginyl synthethase; TSEN = transfer RNA splicing endonuclease; VRK1 = vaccinia-related kinase 1

---

### Introduction

Pontocerebellar hypoplasia represents a group of autosomal recessive neurodegenerative disorders with prenatal onset, predominantly affecting growth and survival of neurons in the cerebellar cortex, the dentate, inferior olivary and ventral pontine nuclei. The variable involvement of supratentorial structures includes ventriculomegaly, neocortical atrophy and microcephaly. Radiologically and pathologically, all subtypes are characterized by hypoplasia and variable atrophy of the cerebellum and pons.

Six subtypes of pontocerebellar hypoplasia have so far been identified. Type 1 (MIM 607596) is characterized by additional loss of motor neurons in the spinal cord, morphologically similar to the hereditary spinal muscular atrophies (Norman, 1961; Goutieres et al., 1977; Barth, 1993, 2000). Recently, an association with the vaccinia-related kinase 1 gene (VRK1) was reported in a single family with a mild variant of pontocerebellar hypoplasia type 1 (Renbaum et al., 2009). In pontocerebellar hypoplasia type 2 (MIM 277470, 612389, 612390), the distinctive feature is dyskinesia and/or dystonia and, more rarely, pure spasticity (Barth et al., 1995). Pontocerebellar hypoplasia type 4 (MIM 225753), previously known as olivopontocerebellar hypoplasia, has a more severe course with prenatal onset of clinical symptoms such as polyhydramnios and contractures. Early postnatal death is often reported, usually due to primary respiratory insufficiency. Typical for pontocerebellar hypoplasia type 4 are the C-shaped inferior olives, indicating an earlier prenatal onset than seen in type 2 (Albrecht et al., 1993; Barth et al., 2007). Neuropathologically, pontocerebellar hypoplasia type 4 and type 2 both display the fragmentation of the cerebellar dentate nuclei. Mutations in the transfer RNA splicing endonuclease subunit gene TSEN54 are responsible for pontocerebellar hypoplasia type 2 and 4 in most European cases. All mutations identified in type 2 cases are missense mutations (TSEN54, TSEN2, TSEN34). In pontocerebellar hypoplasia type 4, nonsense and missense mutations have been identified together (TSEN54) (Budde et al., 2008).

Pontocerebellar hypoplasia types 3, 5 and 6 (MIM 608027, 610204, 611523, respectively) are rare forms of pontocerebellar hypoplasia. Type 3, also known as cerebellar atrophy with progressive microcephaly, is associated with optic atrophy, seizures, hypotonia and short stature (Rajab et al., 2003; Durmaz et al., 2009). Type 3 is mapped to chromosome 7q [markers D7S802 and D7S630 define the borders of the region (Durmaz et al., 2009)] but no gene has yet been identified. Type 5 is characterized by intra-uterine seizure-like activity and a predominantly affected vermis (Patel et al., 2006). No associated locus has been identified. Type 6 has been reported in two families: one with associated mitochondrial respiratory chain abnormalities and the other with progressive encephalopathy, oedema, hypsarrhythmia and optic atrophy-like features. Mutations in the nuclear encoded mitochondrial arginyl transfer RNA synthetase gene (RARS2) have been identified (Edvardson et al., 2007; Rankin et al., 2010).

In this study, we investigated a cohort of 169 patients (141 families) who were referred to our laboratory for molecular genetic testing due to pontocerebellar hypoplasia. We screened the coding regions for TSEN54, TSEN2, TSEN34, TSEN15, RARS2 and VRK1 mutations. In order to define the phenotypical spectrum in patients with the common TSEN54 mutation, brain MRI and the clinical phenotype of patients with the common TSEN54 mutation were compared with patients where we did not find a mutation. Here we show that on MRI, a dragonfly-like pattern of the cerebellum is significantly associated with the common homozygous p.A307S mutation in TSEN54 (100%). The common mutation in TSEN54 is associated with progressive microcephaly, severe lack of motor development, dyskinesia and/or dystonia, central visual impairment and impaired swallowing. These findings, together with a dragonfly-like cerebellum, are highly specific for pontocerebellar hypoplasia type 2 with the common mutation and can be implemented in the clinical and molecular diagnosis of type 2 patients. Compound heterozygotes with a nonsense mutation and a missense mutation in TSEN54 are associated with
a more severe phenotype with pre- and peri-natal onset of symp-
toms, such as polyhydramnios, contractures, dependence on
mechanical ventilation (>1 day after birth) and early death.

Patients and methods

Patient cohort
For this study, we selected a group of 169 patients (141 families)
referred for molecular genetic testing of pontocerebellar hypoplasia-
associated genes. All patients who took part in our study were diag-
nosed with pontocerebellar hypoplasia by referring clinicians. Using
these non-strict selection criteria, we aimed to include typical and
atypical patients that represent the spectrum of cases submitted to
laboratories performing genetic testing. Blood or genomic DNA
samples were provided through neurology, paediatric and clinical
genetic departments worldwide. Samples were submitted to our
department for diagnostics and informed consent was obtained by
referring physicians.

Genetic analysis
The coding regions and exon-intron boundaries of TSEN54, TSEN34,
TSEN2, TSEN15, RARS2 and VRK1 were sequenced on both strands.
If DNA levels were not sufficient, DNA was amplified with the
GenomiPhi V2 DNA Amplification kit (GE Healthcare, Waukesha,
USA) according to the manufacturer’s protocol. For 28 cases, DNA
drawn from affected siblings was available. All coding regions and exon–
intron boundaries for ≥1 case per family were sequenced. Once a
mutation was found, it was verified in the affected sibling. Primer
pair sequences, polymerase chain reaction and sequence conditions
are available upon request. Polymerase chain reaction products
were directly sequenced using BigDye Terminator sequencing kit
and ABI PRISM 3730 DNA analyser (Applied Biosystems, Foster City,
CA, USA) according to the manufacturer’s protocol. Sequences were
analysed using the CodonCode Software version 3.0.1 (Dedham, MA,
USA). Possible variants were confirmed by re-sequencing a new poly-
merase chain reaction product. When available, DNA from parents
was analysed to confirm segregation. One hundred and sixty-seven
control chromosomes (88 individuals) were screened to exclude
polymorphisms. The study design is shown in Fig. 1.

Clinical analysis
Detailed clinical information was available for 85 patients. This
included pre- and peri-natal morbidity and disease course (Table 1).
Additional information requested by questionnaire included specific
questions on (progressive) microcephaly, motor achievements, visual
and feeding behaviour, speech and contractures.

Magnetic resonance imaging analysis
Complete magnetic resonance neuroimages (coronal, sagittal and axial
sections) were available for 50 patients. Prior to DNA analysis, coronal,
sagittal and axial MRIs were qualitatively analysed (by P.G.B. and
B.T.P.T.). Cerebellum, pons, cerebral cortex, ventricles and myelination
were analysed and divided into different categories (for further
explanation see Tables 2 and 3 and Fig. 2A–D).

Statistical analysis
Fisher’s exact test and Chi-square test for trend were used to test
whether there were significant phenotypical differences between the
different mutation groups and the group in whom no mutations were
identified.

Results
We identified disease-causing mutations in 106 of the 169 pa-
tients, representing a mutation frequency of 62.7%. One hundred
patients (59.2%) had a disease causing mutation in TSEN54.
Eighty-eight of these patients were homozygous for the
common mutation (p.A307S) in TSEN54 (52.1%). MRI scans
were available for evaluation from 50 individuals. Twenty of
these 50 patients had the common mutation, in 13 cases we
identified a rare mutation and in the remaining 17 of the
50 imaged cases we did not identify a mutation. All mutations
that we identified were verified in 176 control chromosomes and
none of them were found homozygous in healthy individuals. We
also analysed, but did not identify, mutations in the candidate
gene TSEN15 and the VRK1 gene.

TSEN54 common mutation
Neurological phenotype
Eighty-eight of 169 patients were homozygous for the common
mutation (p.A307S) in TSEN54 (52.1%). Due to the size of this
group, we were able to redefine the phenotype in detail and com-
pare with patients without mutations (Table 1). Pre- and peri-natal
complications, such as polyhydramnios and contractures, were
rare in patients with the common mutation. Neonatal irritability
(jitteriness and/or clonus) and dyskinesia and/or dystonia were

Figure 1
Study design.
Impaired swallowing contributing to failure to thrive and requiring nasogastric tube feeding or percutaneous endoscopic gastrostomy is frequently seen in patients with the common mutation (P < 0.0001). Progressive microcephaly becomes more evident with increasing age and was associated with the common mutation (P < 0.005) (Fig. 3, Roche et al., 1987).

Impaired hand and head control and central visual impairment in the absence of primary optic atrophy were also strongly associated with the presence of the common mutation (P < 0.0005). Primary optic atrophy was ultimately used as an exclusion criterion for the common mutation, as none of the patients with this mutation displayed such a phenotype.

Taking all aforementioned criteria together, these characteristics fit with a pontocerebellar hypoplasia type 2 phenotype.

The number of patients with a symptom is given relative to all patients with information on this symptom. Percentages indicate the proportion of the patients with a symptom relative to all patients with symptom information. ed = early death.

a Significantly associated with the common mutation group, compared to cases where no mutation was identified. The absence of primary optic atrophy was also significantly associated with the mutation.
b One case did not exhibit dyskinesia, dystonia and spasticity, however, this case was <3 months at the time of the examination.
c One case had optic atrophy secondary to glaucoma. Primary optic atrophy was not reported in any of these cases.
d Patient is alive.
e Hand control: G = grasping; I = intentional; Nn = none.
f Postural antigravity control: H = with hip support; Nn = none; S = with shoulder support; T = with high thoracic support; Us = unsupported sitting.

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Clinical symptoms in patients with the common mutation and in patients in whom no mutation was identified</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Homozygous for TSEN54 p.A307S</td>
</tr>
<tr>
<td>(n = 88)</td>
<td></td>
</tr>
<tr>
<td>Prematurity (&lt;38 weeks gestation)</td>
<td>11/63</td>
</tr>
<tr>
<td>Polyhydramnios</td>
<td>3/67</td>
</tr>
<tr>
<td>Jitteriness, clonus</td>
<td>45/50a</td>
</tr>
<tr>
<td>Congenital contractures</td>
<td>1/62</td>
</tr>
<tr>
<td>Microcephaly &lt;−2 SD</td>
<td>73/73</td>
</tr>
<tr>
<td>Progressive microcephaly</td>
<td>67/67a</td>
</tr>
<tr>
<td>Dyskinesia/dystonia</td>
<td>69/72a,b</td>
</tr>
<tr>
<td>Pure spasticity</td>
<td>2/72b</td>
</tr>
<tr>
<td>Impaired swallowing</td>
<td>68/69a</td>
</tr>
<tr>
<td>Central visual impairment</td>
<td>52/60a</td>
</tr>
<tr>
<td>Primary optic atrophy</td>
<td>0/59a,c</td>
</tr>
<tr>
<td>Epileptic seizures, all types</td>
<td>44/54</td>
</tr>
<tr>
<td>Mechanical ventilation &gt;1 day after birth 4/64</td>
<td>6.3</td>
</tr>
<tr>
<td>Median age at last examination</td>
<td>34.5 months (58 patients)</td>
</tr>
<tr>
<td>Survival range (median age of death)</td>
<td>2.5 weeks to 31 yearsd (50 months, 18 patients)</td>
</tr>
<tr>
<td>Hand controle</td>
<td>43 Nn4</td>
</tr>
<tr>
<td>Postural antigravity controlf</td>
<td>28 Nn4</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 2</th>
<th>MRI findings in patients with the common mutation and in patients in whom no mutations were identified</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>TSEN54 p.A307S p.A307S (n = 20)</td>
</tr>
<tr>
<td>Morphological stage</td>
<td>0</td>
</tr>
<tr>
<td>Cerebellar hemispheresa</td>
<td>0</td>
</tr>
<tr>
<td>Ponsb</td>
<td>0</td>
</tr>
<tr>
<td>Vermis folial atrophyce,d</td>
<td>9</td>
</tr>
<tr>
<td>Cerebral cortex</td>
<td>12</td>
</tr>
<tr>
<td>Ventriclesf</td>
<td>6</td>
</tr>
</tbody>
</table>

Reference sequences are NM_207346.2, NM_025265.2, NM_024075.2 and NM_020320.3 (for TSEN54, TSEN2, TSEN34 and RARS2, respectively).

a Based on coronal images, the cerebellar hemispheres were distinguished into different groups: (1) a dragonfly type, with flattened cerebellar hemispheres ('the wings') and a relatively preserved vermis ('the body'); (2) a butterfly type, with a small cerebellum where the proportional size of hemispheres and vermis is preserved; (3) a postnatal atrophy type; and (4) all cases that cannot be categorized under (1)–(3).
b Pons was scored as normal (0), attenuated (1) or flat (2).
c Vermis folia were scored as normal (0), atrophy (1) or severe atrophy (2).
d In one case it was not possible to determine the degree of folial atrophy in the vermis.
e Cerebral cortex was scored as normal (0), mild atrophy with visible sulci (1), moderate or severe atrophy (2) or delayed maturation with immature aspect (3).
f Ventricles were scored as normal (0), anterior > posterior (1) or general dilatation (2).
A wide range of life expectancy was reported. While one child died at the age of 2.5 weeks, one patient is now alive at 31 years of age. We previously established the allele frequency of the common p.A307S mutation in German and Dutch individuals (n = 730) and identified 6 heterozygote genotypes (Budde et al., 2008). Effects of the common mutation on protein function was predicted with Alamut software 1.5 (Interactive Biosoftware, Rouen France) (Tables 5 and 6) (Budde et al., 2008).

Magnetic resonance imaging analysis

Based on coronal images, we divided the cerebellar hemisphere pathology into four different categories (Table 2, Fig. 2A–D): (1) a dragonfly type, with flattened cerebellar hemispheres (‘the wings’) and a relatively preserved vermis (‘the body’); (2) a butterfly type, with a small, normally proportioned cerebellum; (3) a postnatal atrophy type; and (4) the remainder of cases that cannot be categorized in (1–3) above. None of the images showed normal hemispheres. The dragonfly-like cerebellar hemispheres were significantly associated with the presence of the common mutation compared to cases where no mutation was identified (P < 0.0005; Fig. 2A and B). All 20 cases with the common mutation had dragonfly-like hemispheres. Six of the 17 cases of the group without a mutation also showed this MRI phenotype.

The shape of the pons was divided into three different categories: (1) normal; (2) attenuated; or (3) flat. The degree of attenuation of the pons was significantly associated with the presence of the common mutation (P < 0.0005; Fig. 4A).

The shape of the cerebellar folia in the vermis, the atrophy and/or maturity of the cerebral cortex and the size of the ventricles were not significantly associated with patients with a common mutation, compared to patients in whom no mutation was identified (P = 0.213, 0.871 and 0.573, respectively). The vermal folia and the cerebral cortex were relatively preserved. Also, no correlation was found between ventricular size and the presence of the common mutation. Generally, myelination of the cerebral hemispheres was delayed. No signs of demyelination were found.

Additional findings in the common mutation group

In eight patients (40%), mild to severe cerebral cortical atrophy was seen on MRI (Table 2, Fig. 5A). This phenomenon correlates with increasing age, suggesting that cortical atrophy might develop in all cases with pontocerebellar hypoplasia type 2.

One patient (Am1b II.1) had vermal and cerebellar hemispheric cysts (Fig. 5B and C). Autopsy of this patient revealed that the cysts were destructive (Barth et al., 2007). We did not observe cysts in affected family members of this patient. However, cysts were found in one unrelated case where we did not find a mutation.

Genetic, clinical and neuroradiological findings in cases with a rare mutation

In 18 patients (17 families) of our cohort of 169 patients, we identified a rare combination of mutations in TSEN54, TSEN34, TSEN2 or RARS2. In 10 patients we observed a combination of mutations not previously published (Table 4). Effects of these
mutations on protein function or transcription were predicted with Alamut software 1.5 (Interactive Biosoftware, Rouen France) (Tables 5 and 6).

**Severe TSEN54 mutations**

Nine patients were compound heterozygote and we classified their combination of mutations as severe TSEN54 mutations (Table 4). Of these, five (Ch1, Bd1, Ut4, Nu1, Gn6) carried a nonsense mutation plus a common mutation. Three individuals (Se1, Se2, Us15) carried a splice site mutation plus a common mutation. No RNA was available to test for splicing errors. *In silico* analysis suggests loss of a splice donor site in two patients (Se1 and Se2) and skipping of exon 10 in one patient (Us15). Segregation was confirmed by testing parental DNA. One patient (Br1) had three mutations in TSEN54; on one allele she had the common p.A307S mutation; on the second allele she also carried the p.A307S mutation plus another missense mutation, p.S93P (Budde et al., 2008).

All cases had severe congenital symptoms. One patient (Se2) was antenatally diagnosed with cerebellar hypoplasia (gestational age of 19 weeks). In five patients, polyhydramnios was reported (P < 0.05) (Table 4). Contractures were reported in six patients (P < 0.005) (Table 4). All but one case (Bd1) were dependent on mechanical ventilation (P < 0.01). Severe myoclonus was reported in all of them and all but one died in their first year (range: 2 days–16 months, median age at death: 12 days). Additionally, one case (Gn6) is still alive (age at latest examination 6 weeks). In summary, patients who were compound heterozygote for a missense mutation plus nonsense or splice site mutations in TSEN54 were more severely affected than patients homozygous for the common mutation. These patients fit a pontocerebellar hypoplasia type 4 phenotype, which includes early death, prolonged dependency on mechanical ventilation following birth, severe myoclonus, contractures and increased frequency of polyhydramnios. MRIs of these patients reveal pathology comparable to patients with the common mutation in TSEN54 (Tables 2 and 3, Fig. 6A–C). The cerebellar hemispheres are similar, however the vermis is more frequently affected. The most striking difference, compared to the common mutation group and to patients without a mutation, is the immaturity of the cerebral cortex in this

---

**Figure 2** Examples of MRI scores of cerebellum. (A and B) Cerebellar hemisphere score 1: dragonfly type, with flat cerebellar hemispheres and a relatively spared cerebellar vermis (coronal sections, T2-weighted, 9 months). Mild atrophy of the cerebral cortex with visible sulci. Homozygous for common TSEN54 mutation. (C) Cerebellar hemisphere score 2: butterfly type, with hypoplastic cerebellar hemispheres. Decrease in size of the vermis is proportional to the diminution in size of the hemispheres (coronal section, T1-weighted, 7 years). In addition, cerebellar cortical atrophy is seen, as well as mild atrophy of the cerebral cortex with visible sulci. No mutation identified. (D) Cerebellar hemisphere score 3: postnatal atrophy-like on the right side, combined with mild cerebellar hypoplasia on the left (coronal section, T2-weighted, 10 months). In addition there is cerebral cortical atrophy with visible sulci. Heterozygote for uncommon TSEN54 mutation (p.G124V) plus heterozygote for common TSEN54 mutation.
Figure 3  Progressive microcephaly in patients with the common mutation. Frontal-occipital circumference was measured in 38 cases (61 measurements). Measurements of individual patients are connected within the first 3 years of life to illustrate rates of progression. Reference measurements were used from Roche et al. (1987).

Figure 4  Typical MRI seen in the common mutation group. Flat ventral surface of the pons, cerebellar hemispheric and mild vermal hypoplasia. In this case without significant folial atrophy (sagittal sections, T2-weighted, 9 months). The corpus callosum is too thin. Homozygous for common TSEN54 mutation.

Figure 5  Additional findings in patients with the common mutation (A). Neocortical atrophy (sagittal view, T1-weighted, 9 months). Homozygous for common TSEN54 mutation. (B and C) Cerebellar vermal (B) and hemispheric cyst (C). Mid and lateral sagittal sections from Patient Am1b II.1 (T1-weighted Inversion Recovery, 12 months). Homozygous for common TSEN54 mutation.
Table 4 Clinical symptoms in patients with rare mutations in TSEN54, TSEN34, TSEN2 or RARS2

<table>
<thead>
<tr>
<th>Family code</th>
<th>Ch1 II.1</th>
<th>Br1 II.2</th>
<th>Se2 II.1</th>
<th>Dh1 II.1</th>
<th>Vi5 II.1</th>
<th>Ut4 II.1</th>
<th>Nu1 II.1</th>
<th>Se1 II.1</th>
<th>Us15 II.1</th>
<th>Lj1 II.1</th>
<th>Bd1 II.1</th>
<th>Le1 II.1</th>
<th>Pa1 II.1 / II.3</th>
<th>Hg1 II.1</th>
<th>Ex1 II.1</th>
<th>Sf1 II.1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gene</td>
<td>TSEN54</td>
<td>TSEN54</td>
<td>TSEN54</td>
<td>TSEN54</td>
<td>TSEN54</td>
<td>TSEN54</td>
<td>TSEN54</td>
<td>TSEN54</td>
<td>TSEN54</td>
<td>TSEN54</td>
<td>TSEN54</td>
<td>TSEN2</td>
<td>TSEN2</td>
<td>TSEN34</td>
<td>RARS2</td>
<td>RARS2</td>
</tr>
<tr>
<td>(allele B)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregnancy duration (weeks)</td>
<td>31</td>
<td>At term</td>
<td>34 5/7</td>
<td>40 u</td>
<td>38</td>
<td>35</td>
<td>38</td>
<td>39</td>
<td>38 4/7</td>
<td>39 4/7</td>
<td>39 4/7</td>
<td>39 4/7</td>
<td>u at term</td>
<td>38</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Polysymdramnios</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>Jitteriness/clonus</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>u</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>u</td>
<td>+</td>
<td>+</td>
<td>u</td>
<td>+</td>
<td>–</td>
</tr>
<tr>
<td>Congenital contractures</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>u</td>
<td>+</td>
</tr>
<tr>
<td>Microcephaly</td>
<td>u</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>u</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Progressive microcephaly</td>
<td>u</td>
<td>+</td>
<td>ed</td>
<td>+</td>
<td>+</td>
<td>ed</td>
<td>+</td>
<td>ed</td>
<td>u</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>/</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Impaired swallowing</td>
<td>u</td>
<td>+</td>
<td>+</td>
<td>–</td>
<td>+</td>
<td>+</td>
<td>u</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>–</td>
<td>+</td>
<td>+</td>
<td>–</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Central visual impairment</td>
<td>u</td>
<td>+</td>
<td>ed</td>
<td>–</td>
<td>+</td>
<td>ed</td>
<td>+</td>
<td>ed</td>
<td>ed</td>
<td>ed</td>
<td>ed</td>
<td>+</td>
<td>u</td>
<td>+</td>
<td>u</td>
<td>+</td>
</tr>
<tr>
<td>Primary optic atrophy</td>
<td>u</td>
<td>+</td>
<td>u</td>
<td>–</td>
<td>u</td>
<td>u</td>
<td>u</td>
<td>u</td>
<td>u</td>
<td>u</td>
<td>–</td>
<td>–</td>
<td>u</td>
<td>/</td>
<td>u</td>
<td>–</td>
</tr>
<tr>
<td>Epileptic seizures, all types</td>
<td>u</td>
<td>u</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>u</td>
<td>+</td>
<td>u</td>
<td>–</td>
<td>+</td>
<td>+</td>
<td>/</td>
<td>–</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Mechanical ventilation</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>+</td>
<td>ed</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>/</td>
<td>–</td>
</tr>
<tr>
<td>Age at latest examination</td>
<td>9 d</td>
<td>u</td>
<td>6 d</td>
<td>4 yr</td>
<td>11 mo</td>
<td>2 d</td>
<td>8 mo</td>
<td>1 d</td>
<td>2 wk</td>
<td>3 wk</td>
<td>11 mo</td>
<td>6 wk</td>
<td>3 yr</td>
<td>4 yr / 1 mo</td>
<td>4 yr</td>
<td>2 yr</td>
</tr>
<tr>
<td>Age at death</td>
<td>9 d</td>
<td>3 mo</td>
<td>6 d</td>
<td>Alive</td>
<td>Alive</td>
<td>2 d</td>
<td>16 mo</td>
<td>1 d</td>
<td>2 wk</td>
<td>6 wk</td>
<td>12 mo</td>
<td>Alive</td>
<td>Alive</td>
<td>Both alive</td>
<td>alive</td>
<td>alive</td>
</tr>
<tr>
<td>Hand control</td>
<td>ed</td>
<td>Nn</td>
<td>ed</td>
<td>G</td>
<td>I</td>
<td>ed</td>
<td>Nn</td>
<td>ed</td>
<td>ed</td>
<td>Nn</td>
<td>Nn</td>
<td>u</td>
<td>G</td>
<td>Nn/Nn</td>
<td>Nn</td>
<td>u</td>
</tr>
<tr>
<td>Postural antigravity control</td>
<td>ed</td>
<td>Nn</td>
<td>ed</td>
<td>Us</td>
<td>Nn</td>
<td>ed</td>
<td>Nn</td>
<td>ed</td>
<td>ed</td>
<td>Nn</td>
<td>Nn</td>
<td>u</td>
<td>Us</td>
<td>Nn/Nn</td>
<td>Nn</td>
<td>S</td>
</tr>
</tbody>
</table>

Reference sequences are NM_207346.2, NM_025265.2, NM_024075.2 and NM_020320.3 (for TSEN54, TSEN2, TSEN34 and RARS2, respectively).

Plus = Yes; Minus = No; u = unknown; ed = early death; wk = weeks; mo = months; yr = years.

a Hand control: G = grasping; I = intentional; Nn = none.
b Postural antigravity control: H = with hip support; Nn = none; S = with shoulder support; T = with high thoracic support; Us = unsupported sitting.
c Patient from Rankin et al. (2010).
d DNA of patient was no longer available, therefore the genotype of the patient was predicted from sequencing parental DNA.
e Splice site mutation.
Olivopontocerebellar hypoplasia was observed in Patient Ut4. Large midline cava, most likely due to the lack of growth of the cerebral hemispheres, with increased volume of extracerebral CSF and exceptionally large midline cava, most likely due to the lack of growth of the cerebral hemispheres.

In seven cases with pontocerebellar hypoplasia type 4, the maturation of the cerebral cortex was underdeveloped for postconceptional age, which is associated with more severely affected cerebellar phenotype. TSEN54 mutations

Three patients were compound heterozygotes for missense mutations in TSEN54 (Dh1, Vi5 and Lj1; Table 4). One patient (Table 4, Hg1) with a homozygous missense mutation on the other allele (p.Y309C). Two siblings (Pa1 II.1 and II.3) match the common mutation group phenotype in all regards. Pa1 II.1 and II.3 carry a splice site mutation on one allele (c.960+1delGTAAG) and a missense mutation in the cerebellar hemispheres.

Autopsy revealed similar pathology to the MRI. Olivopontocerebellar hypoplasia was observed in Patient Ut4 (Patient 7 and Patient Ut4 in Barth et al., 2007 and Budde et al., 2008, respectively), which included severely reduced folial development in the cerebellar hemispheres and the horseshoe appearance of the inferior olivary nucleus. Autopsy of Se2 revealed a similar pathology with additional severe cerebral immaturity and atrophy most pronounced in the frontal lobes. Motor neurons of the spinal anterior horns were intact.

Rare TSEN54 missense mutations

Three patients were compound heterozygotes for missense mutations in TSEN54 (Dh1, Vi5 and Lj1; Table 4). Two of these patients (Dh1, Vi5) carry the same combination of mutations (p.G124V and p.A307S). Compared to the common mutation group, Patient Dh1 is relatively well. She is able to sit unsupported, grasp, smile and socially interact with her parents. From this perspective it will be interesting to follow up Patient Vi5, who is still young (aged 11 months at last examination). With regard to her MRI, Patient Dh1 (Table 3) is similar to the common mutation group, which suggests that the degree of infratentorial involvement may not relate to postural motor control, central visual impairment and intellectual performance. The MRI of Patient Vi5 shows postnatal atrophy of the cerebellar hemispheres (Table 3, Fig. 2D).

Patient Lj1 was compound heterozygote for the common mutation and the p.Y513D change. She had an early death postnatal death phenotype is associated with more severely affected cerebellar hemispheres, pons, vermis, cerebral cortex and ventricles than observed in cases with the common mutation (Table 3, Fig. 6A–C).

TSEN2 mutations

In two families (Table 4; Le1, Pa1) missense and splice site mutations in TSEN2 were identified. In one patient (Le1, Budde et al., 2008) with a homozygous mutation in TSEN2, motor control (recorded as unsupported sitting and the ability to grasp objects) was better in comparison to the common TSEN54 mutation group. This early postnatal death phenotype is associated with more severely affected cerebellar hemispheres, pons, vermis, cerebral cortex and ventricles than observed in cases with the common mutation (Table 3, Fig. 6A–C).

TSEN34 mutations

One patient (Table 4, Hg1) with a homozygous missense mutation in TSEN34 was similar in symptomatology to the common TSEN54 mutation group, except for the absence of dysphagia (Budde et al., 2008). MRIs of this case show mild involvement of cerebellum and pons (similar to Fig. 2D).

---

**Table 5 Missense and nonsense mutations in pontocerebellar hypoplasia**

<table>
<thead>
<tr>
<th>Gene</th>
<th>Nucleotide position</th>
<th>Protein position</th>
<th>Grantham score</th>
<th>Polyphen</th>
<th>Conservation amino acid</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSEN54</td>
<td>c.371G&gt;T</td>
<td>p.G124V</td>
<td>109</td>
<td>Probably damaging</td>
<td>Highly conserved</td>
<td>–</td>
</tr>
<tr>
<td>TSEN54</td>
<td>c.953delC</td>
<td>p.P318QfsX23</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>TSEN54</td>
<td>c.736C&gt;T</td>
<td>p.Q246X</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>TSEN54</td>
<td>c.1537T&gt;G</td>
<td>p.Y513D</td>
<td>160</td>
<td>Highly conserved</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>TSEN54</td>
<td>c.1027C&gt;T</td>
<td>p.Q343X</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>TSEN54</td>
<td>c.178_215del</td>
<td>p.E60fsX109</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>TSEN54</td>
<td>c.277T</td>
<td>p.S93P</td>
<td>74</td>
<td>Possibly damaging</td>
<td>Highly conserved</td>
<td>–</td>
</tr>
<tr>
<td>TSEN54</td>
<td>c.1056_1057del</td>
<td>p.R353QfsX81</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>TSEN34</td>
<td>c.172C&gt;T</td>
<td>p.R58W</td>
<td>101</td>
<td>Probably damaging</td>
<td>Moderate conserved</td>
<td>–</td>
</tr>
<tr>
<td>TSEN2</td>
<td>c.926A&gt;G</td>
<td>p.Y390C</td>
<td>194</td>
<td>Probably damaging</td>
<td>Moderate conserved</td>
<td>–</td>
</tr>
<tr>
<td>RARS2</td>
<td>c.35A&gt;G</td>
<td>p.Q12R</td>
<td>43</td>
<td>Possibly damaging</td>
<td>Moderate conserved</td>
<td>–</td>
</tr>
<tr>
<td>RARS2</td>
<td>c.1024A&gt;G</td>
<td>p.M342V</td>
<td>21</td>
<td>Probably damaging</td>
<td>Highly conserved</td>
<td>–</td>
</tr>
</tbody>
</table>

*a Predictions were made with Alamut software 1.5 and Grantham score (Grantham, Science 1974).*

---

**Table 6 Splice site mutations in pontocerebellar hypoplasia**

<table>
<thead>
<tr>
<th>Gene</th>
<th>Nucleotide position</th>
<th>Protein position</th>
<th>Splice site mutation*</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSEN54</td>
<td>c.1251A&gt;G</td>
<td>p.P417P</td>
<td>Loss of a splice donor site</td>
</tr>
<tr>
<td>TSEN54</td>
<td>c.1430+2T&gt;A</td>
<td>–</td>
<td>Skip of exon 10</td>
</tr>
<tr>
<td>TSEN54</td>
<td>c.285C&gt;C</td>
<td>p.A95A</td>
<td>Loss of a splice donor site</td>
</tr>
<tr>
<td>TSEN2</td>
<td>c.960+1delGTAAG</td>
<td>–</td>
<td>Skip of exon 7</td>
</tr>
<tr>
<td>RARS2</td>
<td>c.110+5A&gt;G</td>
<td>–</td>
<td>Skip of exon 2</td>
</tr>
</tbody>
</table>

*a Predictions were made with Alamut software 1.5 and Grantham score (Grantham, Science 1974).*

*b Edvardson et al. (2007).*
**RARS2 mutations**

RARS2 mutations were found in two patients (Table 4). One case (Ex1, Rankin et al., 2010) had progressive microcephaly, hypotonia, no dystonia/dyskinesia, impaired swallowing, seizures and lactic acidemia in the neonatal period. MRI findings were comparable to those published previously by others (Edvardson et al., 2007).

The other case (Sf1) had hypotonia, early lethality (age at death 6 days) and high CSF lactate levels, fitting a pontocerebellar hypoplasia type 6 phenotype. Post-mortem examination of this patient revealed a neuropathological profile that fits a pontocerebellar hypoplasia type 1 phenotype, with loss of spinal anterior horn cells and diffuse gliosis. Furthermore, flat cerebellar folia, loss of Purkinje cells and pontocerebellar hypoplasia were found.

**Pontocerebellar hypoplasia type 2 phenotype in the negative mutation group**

We compared the group without mutations (63 patients) to the group with mutations, in order to find characteristics common to both groups, as well as atypical features. Using these criteria, only 13 individuals from the no-mutation group retained all the significant characteristics of the common TSEN54 mutation group (Table 7). However, it must be stated that the clinical profile of the characteristics of these 13 individuals is incomplete.

**Unidentified variants**

Rare sequence variants were not likely to be pathogenic, since they were synonymous mutations, mutations in introns or untranslated regions, or mild amino acid substitutions (Supplementary Table 1).

**Table 7 Inclusion and exclusion criteria in negative mutation group**

<table>
<thead>
<tr>
<th>Inclusion criteria</th>
<th>Exclusion criterion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jitteriness, clonus</td>
<td>Primary optic atrophy</td>
</tr>
<tr>
<td>Progressive microcephaly</td>
<td></td>
</tr>
<tr>
<td>Dyskinesia/dystonia</td>
<td></td>
</tr>
<tr>
<td>Impaired swallowing</td>
<td></td>
</tr>
<tr>
<td>Central visual impairment</td>
<td></td>
</tr>
<tr>
<td>MRI: Cerebellar hemisphere (score 1)&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>MRI: Pons (score 1 or 2)&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
</tr>
</tbody>
</table>

The above-mentioned characteristics were used as inclusion and exclusion criteria in order to study the negative mutation group more closely. Thirteen patients from the negative mutation group fit the pontocerebellar hypoplasia type 2 phenotype.

a Cerebellar hemisphere score as in Tables 2 and 3.
b Pons score as in Tables 2 and 3.

**Discussion**

In this study, we investigated a cohort of 169 patients (141 families) clinically diagnosed with pontocerebellar hypoplasia and determined the contribution of five genes known to be involved in pontocerebellar hypoplasia (TSEN54, TSEN2, TSEN34, RARS2 and VRK1). In addition, we sequenced candidate gene TSEN15 for mutations, since this gene also encodes for a protein-subunit of the TSEN complex. We identified disease-causing mutations in 106 cases, representing a mutation frequency of 62.7%. In 100 patients we identified disease-causing mutations in TSEN54 (59.2%). Eighty-eight of these patients had a homozygous p.A307S mutation in TSEN54 (52.1%). Twelve cases had a rare combination of TSEN54 mutations (7.1%). Three individuals carried mutations in TSEN2 (1.8%). One patient had a mutation in TSEN34 (0.6%).
Two patients carried RARS2 mutations (1.2%). In the genes TSEN15 and VRK1 no pathogenic mutations were found. Most alleles with the p.A307S TSEN54 mutation were from patients of Northern European descent, including cases from the USA and Canada. Exceptional cases were from Israeli, Arab, Turkish and Ibero-American descent.

**TSEN54 common mutation: pontocerebellar hypoplasia type 2**

The common mutation group fits the pontocerebellar hypoplasia type 2 phenotype (Table 7), in which dyskinesia and/or dystonia and severe microcephaly are the major clinical hallmarks, together with pontocerebellar hypoplasia. The presence of progressive microcephaly and the absence of primary optic atrophy can be considered distinctive features for the common mutation. Epileptic seizures are common in the pontocerebellar hypoplasia type 2 group (81.5%) and the probability of developing these increases with age. In some cases it may be difficult to differentiate between seizures and dyskinetic movements.

Life expectancy is difficult to predict as survival ranges from early postnatal (2.5 weeks) to adult death (one case alive at 31 years). Survival will be prolonged with better care such as tube feeding via percutaneous endoscopic gastrostomy and artificial ventilation.

We show that the pontocerebellar hypoplasia type 2 phenotype is distinct and can be used to guide molecular diagnosis. All cases with the common mutation (100%) have a dragonfly-like phenotype on MRI, therefore MRI is recommended and helps in early diagnosis.

**Severe TSEN54 mutations: pontocerebellar hypoplasia type 4**

Nine patients were considered to have a combination of missense and nonsense mutations in TSEN54, leading to more severe symptoms (Table 4) and early death (median age 12 days). These patients fit the pontocerebellar hypoplasia type 4 subtype.

MRI analysis of the TSEN54 severe mutation group deviates in some regards from the common mutation group: analysis of seven cases reveals pericerebral CSF accumulation, persistently wide midline cava, delayed neocortical maturation and more severe involvement of the vermis (Fig. 6A–C). MRI analysis is therefore essential for diagnosis of pontocerebellar hypoplasia type 4.

**RARS2 mutations causing a pontocerebellar hypoplasia type 1-like phenotype in one case**

In one pontocerebellar hypoplasia type 1 case (confirmed by autopsy) we identified disease-causing mutations in RARS2. These mutations were not previously associated with pontocerebellar hypoplasia type 1, but RARS2 mutations are associated with pontocerebellar hypoplasia type 6, featuring mild mitochondrial chain defects, hypotonia, progressive microcephaly and elevated CSF lactate levels. High CSF lactate is not reported in patients with a TSEN mutation. Autopsy was not performed on the previously published patients with pontocerebellar hypoplasia type 6 (Edwardson et al., 2007; Rankin et al., 2010), and therefore a relationship between RARS2 and pontocerebellar hypoplasia type 1 phenotype cannot be excluded until further cases have been studied.

**TSEN2, TSEN34 and rare TSEN54 missense mutations**

In seven cases of pontocerebellar hypoplasia (Le1, Pa1 II.1, Pa1 II.3, Hg1, Dh1, Vi5, Lj1) we identified rare missense mutations in TSEN34 and TSEN54, and nonsense and splice site mutations in TSEN2. They fit the pontocerebellar hypoplasia type 2 phenotype; however Patient Dh1 has a mild clinical phenotype compared to the common TSEN54 mutation group. Since this group of patients is small in number, more individuals will be necessary to draw a specific phenotypical profile.

**Unsolved cases**

The mutation-negative group is phenotypically heterogeneous in contrast to the common mutation group. Only 13 of the 63 cases fulfilled the common mutation characteristics (criteria in Table 7). Information on some of these characteristics is missing in these 13 individuals, showing that sufficient clinical information and MRI are essential for confident clinical diagnosis and genetic analysis. Untranslated regions, introns or mutations in other genes may underlie the pathogenesis in these cases.

All patients referred by clinical geneticists or neurologists with the clinical or radiological diagnosis pontocerebellar hypoplasia were entered into this study reflecting common clinical practice. Taking these non-strict selection criteria into account, it remains possible that congenital glycosylation disorders, mitochondrial disorders or other diseases underlie the neurological findings in some of the unsolved cases (Denecke et al., 2005; Scaglia et al., 2005; van de Kamp et al., 2007). In case of sensorineural hearing loss and a simplified gyral pattern, X-linked calcium/calmodulin-dependent serine protein kinase mutations should be considered (Najm et al., 2008). One should consider progressive encephalopathy, oedema, hypsarrhythmia and optic atrophy syndrome when a case presents with these symptoms (Somer, 1993). Stricter inclusion criteria might increase the percentage of mutation-positive cases.

Furthermore, the unsolved cases suffer from a higher rate of premature births (34.5%) than the common mutation group (17.5%). In these cases, the severe prematurity (<32 weeks) may be associated with pontocerebellar disruption, developmental delay and the occurrence of seizures (Messerschmidt et al., 2008). Four (13.8%) of the unsolved cases were severely premature (born at 27 and 29 weeks, two others were born at 32 weeks). In the common TSEN54 mutation group there were three cases (4.8%) with severe prematurity (one case at 29 weeks and twins at 30 4/7 weeks, Graham et al., 2010).
Unclassified variants

In three cases, we cannot exclude that the missense mutations found on one allele are not associated with pontocerebellar hypoplasia (TSEN54 p.N347Y, p.R374C and TSEN34 p.R279C, Supplementary Table 1). Since it is not possible to detect large deletions by direct sequencing, we cannot rule out the possibility that these variants are pathogenic in combination with a deletion on the opposite allele.

Disease mechanism

It is difficult to define a common pathway in the different genes associated with pontocerebellar hypoplasia. However all genes, apart from VRK1, play a role in protein synthesis and transfer RNA processing in particular. RARS2 encodes for mitochondrial arginyl transfer RNA synthetase, which charges arginine to specific transfer RNAs during protein synthesis. TSEN2, TSEN34, TSEN54 and TSEN15 encode for the transfer RNA splicing endonuclease, which plays a role in intronic transfer RNA splicing (http://lowelab.uchc.edu/GRNAdb/) (Paushkin et al., 2004). Alternative functions of these proteins might play a role in a common pathway responsible for pontocerebellar hypoplasia (Paushkin et al., 2004). Other neurodegenerative diseases such as Charcot-Marie-Tooth disease and leukoencephalopathy with brainstem and spinal cord involvement and elevated lactate, are also associated with mutations in transfer RNA synthetase genes (Seburn et al., 2006; Scheper et al., 2007; Antonellis and Green, 2008; Park et al., 2008). Patients with nonsense mutations in TSEN54 show a more severe phenotype, which suggests that loss of function of the TSEN54 protein is the underlying disease mechanism. Further research is required to investigate why mutations in transfer RNA processing genes lead to pontocerebellar hypoplasia.

Conclusion

Here we present evidence that the common homozygous mutation in TSEN54 can be predicted reliably from the pontocerebellar hypoplasia type 2 phenotype. There is a strong association with flat dragonfly-like cerebellar hemispheres, a flat pons, dyskinasia and/or dystonia, neonatal irritability, central visual impairment, the absence of optic atrophy and severe cognitive and motor impairment. More severe TSEN54 mutations are associated with early postnatal death, contractures, polyhydramnios and ventilatory problems. MRI analysis reveals severe cerebral immaturity of the cortex, which assists in establishing a diagnosis of pontocerebellar hypoplasia type 4. Our data provide further evidence that pontocerebellar hypoplasia type 2 and 4 result from a common spectrum of mutations, mainly affecting TSEN54. The homogeneity of the phenotype, both from a clinical perspective and by neuroimaging, correlates strongly with the genotype and can facilitate early diagnosis and assist in molecular genetic testing. A clinical and/or neuroradiological pontocerebellar hypoplasia type 2 profile is shared with 13 unsolved cases, suggesting the involvement of other unidentified genes or the involvement of non-coding regions in the TSEN or RARS2 genes in pontocerebellar hypoplasia. In addition, we show that pontocerebellar hypoplasia type 1 together with elevated CSF lactate may be caused by RARS2 mutations. Together these data enhance the clinical description of pontocerebellar hypoplasia and will assist with the neuroradiological and genetic diagnosis of pontocerebellar hypoplasia.

Acknowledgements

We thank M.B. de Wissel-Dijns for technical assistance. We are grateful to Prof. J.M.B.V. de Jong, Prof. M. de Visser and K. Ritz for critical reading of the manuscript. We acknowledge the contribution of subject’s data and DNA samples by S. Shallat, Peoria Medical Centre, Peoria, IL, USA; W. Deppe, Klinik Bavaria, Kreichsa; H. Brunner, Radboud University Nijmegen; Miranda Split, The Institute For Human Genetics, Newcastle upon Tyne, UK; Helen Cox, West Midlands Regional Clinical Genetics Service, Birmingham Womens Hospital, Edgbaston, Birmingham, UK; M. Steinlin, University Hospital, Bern; A. Böhring, Westfälische Wilhelms-Universität, Münster, Germany; S. Gebre-Medhin, Universal Hospital, Lund, Sweden; K. Schoppmeyer, Universitätsklinikum Leipzig, Germany; D. Rowitch, Departments of Paediatrics, Neurosurgery and Howard Hughes Medical Institute, UCSF, San Francisco, USA; M. Koch, Neuropaediatrie, Vesteiche Kinder-Jugendklinik, Datteln.

Funding

Financial support was kindly provided by the Hersenstichting Nederland KS2009(1)-81 and the AMC Graduate School, University of Amsterdam. Y.J.C. acknowledges the Manchester NIHR Biomedical Research Centre.

Supplementary material

Supplementary material is available at *Brain* online.

References


Appendix 1

PCH consortium

Nathalie Van der Aa, Department of Medical Genetics, University and University Hospital Prins Boudewijnlaan 43, Edgem, Antwerp, Belgium. Willem F. M. Arts, Department of Paediatric Neurology, Erasmus Medical Center - Sophia Children’s Hospital, P.O. Box 2060, 3000 CB Rotterdam, The Netherlands. Lesley C. Ades, Department of Clinical Genetics, The Children’s Hospital at Westmead, Sydney Australia 2145, and Discipline of Paediatrics and Child Health, University of Sydney, Sydney Australia. Nadia Bahi-Buisson, Hopital Necker-Enfants Maladies Universit´e Paris Descartes Service de Neurop´ediatrie et Maladies M´etaboliques, Paris, France. Roberta Battini, Department of Developmental Neuroscience, IRCCS Stella Maris, Calambrone, Pisa, Italy. Olaf Bodamer, Institute for Inherited Metabolic Diseases, Paracelsus Medical University and University Children’s Hospital, Strubergasse 21, A-5020 Salzburg, Austria. Eugen Boltshauser, Department of Paediatric Neurology, Children’s University Hospital, CH-8032 Z¨urich, Switzerland. Kym Boycott, Department of Genetics, Children’s Hospital of Eastern Ontario, 401 Smyth Road, Ottawa, Ontario, K1H 8L1, Canada. Louise Brueton, West Midlands Regional Clinical Genetics service, Birmingham Womens Hospital, Edgbaston Birmingham, UK. Wim Brussel, Department of Pediatrics, Rijnstate Hospital, Wagonlaan 55, 6815 AD Arnhem, The Netherlands. K. E. Chandler, Genetic Medicine, Manchester Academic Health Science Centre, University of Manchester, Central Manchester University Hospitals NHS Foundation Trust, St. Mary’s Hospital, Oxford Road, Manchester M13 9WL, UK. Frances M. Cowan, Consultant/Hon. Senior Lecturer in Perinatal Neurology, Department of Paediatrics, Hammersmith Hospital, Imperial College London, DuCane Road, London W12 OHS, UK. Yanick Crow, Genetic Medicine, University of Manchester, Manchester Academic Health Science Centre, Central Manchester Foundation Trust University Hospitals, Manchester, UK. Otfrid Debus, Clemenshospital - Childrens Hospital, M¨unster, Germany. Ercan Demir, Department of Pediatric Neurology, Gazi University, Ankara, Turkey, Gazi Universitesi Tip Fakultesi, Gazi Hastanesi, Cecuk Sagl˘i ve Hastaliklari ABD, Be¸seveler, Ankara, Turkey. Jacqueline Eason, Clinical Genetics Department, The Gables, Nottingham City Hospital Campus, Hucknall Road, Nottingham NG5 1PB, UK. Colin D. Ferrie, Department of Paediatric Neurology, Leeds General Infirmary, Leeds, UK. Richard B. Fisher, Consultant in Clinical Genetics, Northern Genetics Service, Teeside Genetics Unit, The James Cook University Hospital, Middlesbrough TS4 3BW, UK. Nicola Foulds, 1. Wessex Clinical Genetics Services, Southampton University Hospitals Trust, Southampton, UK. 2. Academic Unit of Genetic Medicine, Southampton University, Southampton, UK. Jeremy L. Freeman, Children’s Neuroscience Centre, The Royal Children’s Hospital Melbourne, 50 Flemington Road, Parkville, 3052, Victoria, Australia. Rob Gooskens, Rudolf Magnus Institute for Neuroscience, Department of Childneurology, University Medical Centre Utrecht, Lundlaan 6, 3584 EA Utrecht. Eugenio Grillo,
Department of Neurology, Hospital Infantil Joana de Gusmão, Florianopolis, Santa Catarina, Brazil. Martin Haeussler, Fruehdiagnozcentreum Wuerzburg, Center for Social Pediatrics, University of Wuerzburg, Josef-Schneider-Strasse 2, 97080 Wuerzburg, Germany. Gerard Hageman, Department of Neurology, Medical Spectrum Twente, P.O. Box 50000, 7500 KA Enschede. Gerhard Hammersen, CNOFP’sche Kinderkliniek, St. Johannis Mühlgasse 19, D-90419, Nürnberg, Germany. Denise Horn, Institute of Medical Genetics, Charité, University Medicine of Berlin, Augustenburger Platz 1, 13353 Berlin, Germany. Bertrand Isidor, Service de Génétique Médicale, CHU Nantes, Nantes. Marjo S. van der Knaap, Department of Child neurology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands. Wolfram Kress, Institute of Human Genetics, University of Wuerzburg, Biozentrum, Am Hubland 97074 Wuerzburg, Germany. Peter M. Kroisel, Institute of Human Genetics, Medical University of Graz, Harrachgasse 21, 8010 Graz, Austria. Märtens Kyllerman, The Queen Silvia Children’s Hospital, Gothenburg University, S-416 85 Göteborg, Sweden. A. M. A. Lachmeijer, Afdeling Klinische Genetica, Vrije Universiteit medisch centrum, Polikliniek, Receptie D, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands. Vincenzo Leuzzi, Department of Child Neurology and Psychiatry - La Sapienza Università di Roma-Via dei Sabelli 108, 00141 Rome, Italy. Roelienke J. Lunsing, Department of Paediatric Neurology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands. George McGillivray, Murdoch Children’s Research Institute, Royal Children’s Hospital, Melbourne, Australia. Susanne Möllmann, Ekenhoff 25, 49545 Tecklenburg. Francesco Muntoni, UCL Institute of Child Health and Great Ormond Street Hospital, Du Cane Road, London, UK. Andrea H. Nemeth, Churchill Hospital and University of Oxford, Churchill Drive, Headington, Oxford, OX37L. UK. Whitney Neufeld-Kaiser, University of Washington, Maternal Fetal Medicine and Medical Genetics, 1959 NE Pacific Street, Box 356159, Seattle, WA 98195-6159, USA. Onno van Nieuwenhuizen, Department of Child Neurology, Rudolf Magnus Institute for Neuroscience, Utrecht University, The Netherlands. Robert Ouvrier, Petre Foundation Professor of Paediatric Neurology, The University of Sydney and The Department of Neurology, The Children’s Hospital at Westmead, Hawkesbury Road, Westmead NSW 2145, Australia. Beatrix Pälmsfay, Bethesda Children Hospital, Department of Neurology Budapest Ilka u.57,1043-Hungary. E. A. J. Peeters, Child Neurologist, Juliana Children Hospital, Sportlaan 600, 2566 MJ, The Hague, The Netherlands. Joanna J. Phillips, Division of Neuropathology, Department of Pathology, University of California, San Francisco, CA 94143, USA. Susan Price, Virtual Academic Unit, CDC, Northampton General Hospital, Northampton United Kingdom, NN1 5BD. Julia Rankin, Department of Clinical Genetics, Royal Devon and Exeter NHS Foundation Trust (Heavitree), Gladstone Road, Exeter, EX1 2ED, UK. Luc Régal, Pediatric Metabolic Center, University Hospital Leuven, Herestraat 49, 3000 Leuven, Belgium. J. F. de Rijk-van Andel, Department of Pediatric Neurology, Amphia Hospital location Langendijk, Langendijk 75, 4819 EV Breda, The Netherlands. Filip Roelens, Child Neurology, H. Hart Hospital, Wilgenstraat 2, 8800 Roeselare Belgium. Joe C. Rutledge, University of Washington School of Medicine, Department of Laboratories, Seattle Children’s Hospital, 4800 Sandpoint Way NE, Seattle, WA 98115 USA. Monique M. Ryan, Children’s Neurosciences Centre, Royal Children’s Hospital, Floremonth Road, Parkville, 3052 Victoria, Australia. Rainer Seidl, Department of Pediatrics, Division Neuropediatrics, Medical University Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria. Nina C. Sellerer, Department of Biochemical Genetics, Dr von Hauner Children’s Hospital Ludwig-Maximilians-University, Munich, Germany. Nora L. Shannon, Clinical Genetics Department, The Gables, Nottingham City Hospital Campus, Hucknall Road, Nottingham NG5 1PB, UK. Deborah A. Sival, Department of Pediatrics, Beatrix Children’s Hospital, University Medical Center Groningen University of Groningen, Hanzeplein 1, 9700RB, Groningen, the Netherlands. I. N. Snoeck, Department of Neuropediatrics, Haga Teaching Hospital/Juliana Children’s Hospital, Sportlaan 600 2566 MJ, The Hague, The Netherlands. Rachel Straussberg, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. Marina A. J. Tijssen, Department of Neurology, Academic Medical Centre, University of Amsterdam, P.O. Box 22660, 1100 DD Amsterdam, The Netherlands. Patrick Verloo, Department of Child Neurology and Metabolic Diseases, University Hospital Ghent, Belgium. L. S. de Vries, Department Neonatology, Wilhelmina Children’sHospital, University Medical Centre, Utrecht, The Netherlands. David Wargowski, Director and Chief, Department of Pediatrics Clinic, Division of Genetics and Metabolism University of Wisconsin School of Medicine and Public Health, 1500 Highland Avenue Madison, Wisconsin 53705. Andrew N. Williams, Virtual Academic Unit, CDC, Northampton General Hospital, Northampton NN1 5BD, UK. Christian Windpassinger, Institute of Human Genetics, Medical University of Graz, Harrachgasse 21, 8010 Graz, Austria.